IL220308A0 - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
IL220308A0
IL220308A0 IL220308A IL22030812A IL220308A0 IL 220308 A0 IL220308 A0 IL 220308A0 IL 220308 A IL220308 A IL 220308A IL 22030812 A IL22030812 A IL 22030812A IL 220308 A0 IL220308 A0 IL 220308A0
Authority
IL
Israel
Prior art keywords
vaccine compositions
vaccine
compositions
Prior art date
Application number
IL220308A
Other languages
English (en)
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of IL220308A0 publication Critical patent/IL220308A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL220308A 2009-12-22 2012-06-11 Vaccine compositions IL220308A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (1)

Publication Number Publication Date
IL220308A0 true IL220308A0 (en) 2012-07-31

Family

ID=43797591

Family Applications (1)

Application Number Title Priority Date Filing Date
IL220308A IL220308A0 (en) 2009-12-22 2012-06-11 Vaccine compositions

Country Status (13)

Country Link
US (3) US20130034573A1 (cg-RX-API-DMAC7.html)
EP (2) EP3257525A3 (cg-RX-API-DMAC7.html)
JP (2) JP6007105B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120120185A (cg-RX-API-DMAC7.html)
CN (2) CN107412754A (cg-RX-API-DMAC7.html)
AU (1) AU2010334428B2 (cg-RX-API-DMAC7.html)
CA (1) CA2785585A1 (cg-RX-API-DMAC7.html)
IL (1) IL220308A0 (cg-RX-API-DMAC7.html)
MX (1) MX337070B (cg-RX-API-DMAC7.html)
NZ (2) NZ600978A (cg-RX-API-DMAC7.html)
RU (1) RU2581020C2 (cg-RX-API-DMAC7.html)
SG (2) SG181628A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011077309A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101776976B1 (ko) * 2010-02-21 2017-09-08 바이엘 헬스케어 엘엘씨 생체분자의 활성화 및 접합 방법
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
SG11202100371RA (en) * 2018-07-19 2021-02-25 Helixmith Co Ltd Lyophilized pharmaceutical compositions for naked dna gene therapy
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (cg-RX-API-DMAC7.html) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69532767T2 (de) 1994-11-28 2004-08-12 Thomas Jefferson University Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1010007B1 (en) * 1997-07-31 2004-01-21 Metra Biosystems, Inc. Collagen-peptide assay method
PT1007546E (pt) * 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP1475101B1 (en) * 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
EP1535930B1 (en) * 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antibody specific to central nervous system tau protein
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
KR101531400B1 (ko) * 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
SI1684719T1 (sl) * 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
ATE500848T1 (de) * 2005-05-24 2011-03-15 Neovacs Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein
EP1940461B1 (en) * 2005-11-02 2014-01-08 Duke University Concurrent chemotherapy and immunotherapy
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
AR069989A1 (es) * 2007-12-28 2010-03-03 Baxter Int Formulaciones de vwf recombinantes

Also Published As

Publication number Publication date
US20130034573A1 (en) 2013-02-07
EP2515934A2 (en) 2012-10-31
RU2012131162A (ru) 2014-01-27
CA2785585A1 (en) 2011-06-30
AU2010334428A1 (en) 2012-07-05
MX337070B (es) 2016-02-11
JP2013515049A (ja) 2013-05-02
JP6007105B2 (ja) 2016-10-12
NZ600978A (en) 2014-08-29
WO2011077309A3 (en) 2011-10-06
MX2012007283A (es) 2012-07-30
WO2011077309A2 (en) 2011-06-30
JP2015180667A (ja) 2015-10-15
EP3257525A3 (en) 2018-02-28
EP2515934B1 (en) 2017-05-17
EP3257525A2 (en) 2017-12-20
SG10201408505SA (en) 2015-02-27
CN102762224A (zh) 2012-10-31
KR20120120185A (ko) 2012-11-01
NZ629256A (en) 2016-02-26
CN107412754A (zh) 2017-12-01
US20190365886A1 (en) 2019-12-05
RU2581020C2 (ru) 2016-04-10
SG181628A1 (en) 2012-07-30
JP6146927B2 (ja) 2017-06-14
US20150087815A1 (en) 2015-03-26
AU2010334428B2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
IL217008A0 (en) Vaccine
ZA201109176B (en) Homeglobin compositions
IL217949A0 (en) Pesticdal compositions
GB0913681D0 (en) Immunogenic composition
GB0906515D0 (en) Fungical compositions
IL219891B (en) Lipopeptide preparations
ZA201109312B (en) Compositions
GB201015132D0 (en) Vaccine composition
GB0910046D0 (en) Novel compositions
IL242592A (en) Immunogenic compounds
PL2402032T3 (pl) Kompozycja immunogenna
IL214127A0 (en) Vaccine compositions
GB201006165D0 (en) Vaccine
GB0910045D0 (en) Novel compositions
EP2252326A4 (en) VACCINE COMPOSITIONS
IL216102A0 (en) Combined measles-malaria vaccine
EP2640418A4 (en) IMMUNOGENIC COMPOSITIONS
GB0913680D0 (en) Immunogenic composition
IL220308A0 (en) Vaccine compositions
GB201000522D0 (en) Vaccine
GB0905165D0 (en) Compositions
IL217194A0 (en) Vaccine
ZA201301908B (en) Immunogenic compositions
GB0908963D0 (en) Compositions
GB0912975D0 (en) Formulations